Evidence map›Paper›PMID 40354628›Full record

ArticleJMIR public health and surveillance2025

Epidemic Trends and Spatial Distribution Characteristics of Hepatitis B in China: Surveillance Study.

Xiaoxue Li, Jie Liang, Lanqing Ma, Shijie Shen, Xueying Han, Tao Sun, Heng Guo

Abstract read
In one paragraph

Article in JMIR public health and surveillance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoxue LiDepartment of Public Health, Shihezi University School of Medicine, Xinjiang, No. 59, North 2nd Rd, Hong-Shan District, Shihezi, 832000, China, 86 18909932079.ORCID 0009-0001-9104-5807
Jie LiangKey Laboratory for Major Infectious Disease Monitoring in the Northern Frontier Region of the Corps, Shihezi, China.ORCID 0009-0003-3037-6439
Lanqing MaDepartment of Public Health, Shihezi University School of Medicine, Xinjiang, No. 59, North 2nd Rd, Hong-Shan District, Shihezi, 832000, China, 86 18909932079.ORCID 0009-0003-1402-7554
Shijie ShenDepartment of Public Health, Shihezi University School of Medicine, Xinjiang, No. 59, North 2nd Rd, Hong-Shan District, Shihezi, 832000, China, 86 18909932079.ORCID 0000-0001-6047-1785
Xueying HanDepartment of Public Health, Shihezi University School of Medicine, Xinjiang, No. 59, North 2nd Rd, Hong-Shan District, Shihezi, 832000, China, 86 18909932079.ORCID 0009-0008-2860-5649
Tao Sun *Key Laboratory for Major Infectious Disease Monitoring in the Northern Frontier Region of the Corps, Shihezi, China.ORCID 0009-0009-5480-2459
Heng Guo *Department of Public Health, Shihezi University School of Medicine, Xinjiang, No. 59, North 2nd Rd, Hong-Shan District, Shihezi, 832000, China, 86 18909932079.ORCID 0000-0001-6961-7920

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatitis B is an important public health challenge facing China. Understanding the long-term epidemiological trends and evolving spatial distribution patterns is critical for optimizing prevention strategies and achieving the World Health Organization's 2030 hepatitis elimination targets. Objective: This study aimed to explore the epidemic trends and spatial distribution characteristics of hepatitis B in China from 2004 to 2020. Methods: This study used data on hepatitis B incidence from 2004 to 2020 from the China Public Health Science Data Center to analyze the time trend of hepatitis B incidence by joinpoint regression. The age-period-cohort model was used to analyze the age, period, and cohort effects of hepatitis B onset. Spatial autocorrelation analysis was used to explore the spatial distribution characteristics of hepatitis B in China. Results: From 2004 to 2020, China reported a total of 17,449,842 cases of hepatitis B, with an average annual incidence rate of 76.30/100,000. The incidence of hepatitis B in China showed an increasing trend from 2004 to 2007, with an average annual percentage change (AAPC) of 9.49 (95% CI 2.12-17.39), and a decreasing trend from 2007 to 2014, with an AAPC of -3.77 (95% CI -5.93 to -1.55). The incidence of hepatitis B in China tended to be stable from 2014 to 2020, with an AAPC of -0.46 (95% CI -2.86 to 2.01). Age, period, and cohort effect significantly affect the incidence of hepatitis B. The age effect showed that the incidence rate of hepatitis B reached its peak at the age of 22 years, with an average incidence rate of 176.173/100,000. The period effect showed that the highest level during the study period occurred during 2004-2006. The cohort effect showed that the risk of hepatitis B increased first and then decreased, with the turning point of 1924-1974. The incidence of hepatitis B varies significantly among regions. The incidence in the northeast and northwest regions has decreased, that in the south and southwest regions has increased, and that in other regions has remained stable. Conclusions: China has achieved remarkable results in the prevention and control of hepatitis B, but there are still differences in the incidence rate among different age groups and regions. These results suggest the need to further strengthen the identification and screening of high-risk populations and promote supplementary adult hepatitis B vaccination. Future intervention strategies should fully consider regional differences, implement precise intervention measures based on the epidemic trends and spatial distribution characteristics of each region, optimize resource allocation, and enhance the overall effectiveness of hepatitis B prevention and control.

Indexed as

EpidemicsHepatitis BPopulation SurveillanceAdolescentAdultAgedChildChild, PreschoolChinaFemaleHumansIncidenceInfantMaleMiddle AgedSpatial AnalysisAPC modelhepatitis Bjoinpoint regression analysispublic healthspatial epidemiologyvaccination

Identifiers

PMID40354628
PMCPMC12088607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.